June 5, 2017 / 4:02 PM / 2 months ago

BRIEF-Nanobiotix says Phase I/II head and nack cancer trial shows promising results

1 Min Read

June 5 (Reuters) - NANOBIOTIX SA

* NANOBIOTIX : PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING

* NANOBIOTIX : PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING

* ‍7 OUT 9 PATIENTS HAD COMPLETE REPONSE AT 10% DOSE LEVEL OR MORE​

* FOLLOW UP SHOWS A POTENTIAL IMPACT ON LONG TERM DISEASE CONTROL

* ‍AMENDMENT FILED FOR A DOSE EXPANSION COHORT OF 44 ADDITIONAL PATIENTS​

* ‍Plan to Open This Study in United States​

* ‍VERY GOOD SAFETY PROFILE WITH NO AES AND SAES IN STAGE III/IV IN FRAIL PATIENTS OLDER THAN 70 YEARS OLD​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below